meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - (neo)adjuvant (NA)
mHNSCC - 1st line (L1)
mHNSCC - L1 - all population
2
mHNSCC - L1 - PDL1 positive
4
mHNSCC - 2nd line (L2)
mHNSCC - L2 - all population
4
mHNSCC - L2 - PDL1 negative
2
mHNSCC - L2 - PDL1 positive
1
hepatocell cancer (HCC)
1
immune chekpoint inhibitors
anti-PD-(L)1
durvalumab based treatment
durvalumab alone
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus 5FU plus platin
Immune checkpoint association
durvalumab plus tremelimumab
versus all
vs chemotherapy
vs platinum-based chemotherapy
vs platinum derivate
vs cisplatin
vs Standard of Care (SoC)
vs HER inhibitor
vs EGFR inhibitor
vs cetuximab based chemotherapy
vs cetuximab plus platin plus 5FU
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs tremelimumab
vs anti-PD-(L)1
vs durvalumab based treatment
vs durvalumab alone
vs non active control
vs no additional treatment
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
nivolumab alone
title
Standard of Care (SoC)
title
CheckMate 141, 2016 NCT02105636 mHNSCC - L2 - all population 240/121
Pathology:
mHNSCC - L2 - all population;
mHNSCC - L2 - all population
CheckMate 141, 2016
nivolumab alone
1
T1
Standard of Care (SoC)
0
T0